Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.
Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
But can the novel antigen be targeted effectively? Immatics reckons it can, with the right dose and the right manufacturing process.
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.